Stock Financial Ratios, Dividends, Split History

BIO / Bio-Rad Laboratories, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)7,211.57
Book Value ($M)2,614.56
Book Value / Share107.59
Price / Book2.76
NCAV ($M)545.61
NCAV / Share22.45
Price / NCAV13.35
Share Statistics
Weighted Average Number Of Shares Outstanding Basic 29,186,000
Preferred Stock Shares Outstanding 0
Weighted Average Number Of Diluted Shares Outstanding 29,409,000
Common Shares Outstanding2 5,125,441
Common Shares Outstanding 24,236,681
Scoring Models
Piotroski F-Score5.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.04
Return on Assets (ROA)0.03
Return on Equity (ROE)0.05
Balance Sheet (mrq) ($M)
Quick Ratio3.08
Current Ratio4.40
Income Statement (mra) ($M)
Sales Revenue Net2,019,441,000.00
Operating Income166.71
Net Income113.10
Earnings Per Share Basic3.87
Earnings Per Share Diluted3.85
Cash Flow Statement (mra) ($M)
Cash From Operations186.20
Cash from Investing-166.87
Cash from Financing-166.87
Identifiers and Descriptors
Central Index Key (CIK)12208
Related CUSIPS
090572907 090572957

Split History

Stock splits are used by Bio-Rad Laboratories, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

13h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

13h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Related News Stories

Bio-Rad Banks on Solid Global Scenario, Competition Rife

2018-06-08 zacks
On Jun 7, we initiated a research report on Bio-Rad Laboratories, Inc. (BIO - Free Report) . We are upbeat about the company delivering a robust performance overseas, while a tough competitive landscape is a concern. The stock carries a Zacks Rank #3 (Hold). (78-0)

BIO 2018 is the International Convention’s 25th Year

2018-06-04 biospace
The BIO International Convention will be officially running from June 4 through June 7, although activities began on Friday, June 1. Hosted by the Biotechnology Innovation Organization (BIO), the convention represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organization across the U.S. and the world. (10-0)

Bio-Rad (BIO) Up 13.5% in 3 Weeks Post Solid Q1 Earnings

2018-05-29 zacks
Shares of Bio-Rad Laboratories, Inc. (BIO - Free Report) have gained 13.5% since the release of first-quarter 2018 results on May 8. (37-0)

Bio-Rad Laboratories (BIO) Q1 2018 Results - Earnings Call Transcript

2018-05-09 seekingalpha
Good afternoon, ladies and gentlemen, and welcome to the Bio-Rad Laboratories First Quarter 2018 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. As a reminder, this conference call is being recorded. (10-0)

Medical Product Stocks May 8 Earnings List: HSIC, PEN & More

2018-05-08 zacks
We are on the last leg of first-quarter earnings season. Per the latest Earnings Preview, already 409 S&P 500 members have reported financial results and the overall performance reflects many positive signs, buoying optimism among investors. The latest earnings scorecard highlights 24% increase in total earnings on 9.3% higher revenues. The beat ratio has been impressive as well with 78% companies surpassing bottom-line expectations and 75. (17-0)

CUSIP: 090572207